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Most of the few patients with homozygous CD70 deficiency described to date
suffered from EBV-related malignancies in early childhood. We present a woman with
CD70 deficiency diagnosed in adulthood. She presented in childhood with recurrent
airway infections due to encapsulated bacteria, herpes zoster and a fulminant EBV
infection followed by chronic EBV infection with mild lymphoproliferation and severe
gingivitis/periodontal disease with high EBV viral load in saliva and gingival plaques
as an adult. Up to the age of 24 years she developed no malignancy despite
constant EBV viremia since primary EBV infection 15 years previously. Immunologic
evaluation in childhood showed hypogammaglobulinemia with impaired polysaccharide
responsiveness. She has been stable on immunoglobulin substitution with no further
severe viral infections and no bacterial airway infections in adulthood. Targeted panel
sequencing at the age of 20 years revealed a homozygous CD70 missense mutation
(ENST00000245903.3:c.2T>C). CD70 deficiency was confirmed by absent CD70
expression of B cells and activated T cell blasts. The patient finished high school, persues
an academic career and has rarely sick days at college. The clinical course of our patient
may help to counsel parents of CD70-deficient patients with regard to prognosis and
therapeutic options including haematopoetic stem cell transplantation.
Keywords: primary immunodeficiency, CVID, CD70-deficiency, EBV, gingivitis
Krüger et al. CD70 Deficiency With Severe Gingivitis
INTRODUCTION
CD70 and CD27 deficiencies are rare, autosomal recessively
inherited disorders with an increased susceptibility to Epstein-
Barr virus (EBV)-associated lymphoproliferation as well as
hypogammaglobulinemia [reviewed in (1)]. Six individuals with
CD70 deficiency have been described to date (2–4). CD70 is
expressed on activated B cells and strongly upregulated upon
EBV infection. The CD70 ligand, CD27, is predominantly
expressed on T and memory B cells. The CD27–CD70 axis
appears to be crucial for the induction of EBV-specific T cell
immunity as well as T cell-mediated surveillance of B cells (2).
We describe the clinical course of a now 24-year-old woman with
a recessive-inherited homozygous CD70 missense mutation. The
patient is the first child born to consanguineous Turkish parents.
A younger brother is healthy.
PATIENT’S HISTORY
Infections
The patient suffered from recurrent viral and severe bacterial
airway infections since the second year of life. Chronic
productive cough, particularly on physical exertion and at night
did not improve upon treatment with inhaled ß2-agonists or
inhaled corticosteroids. Following recurrent pneumonia with
detection of encapsulated bacteria (Streptococcus pneumoniae
and Haemophilus influenzae) consolidation of the middle lobe
and bronchiectasis were diagnosed at the age of 7 years. Bacterial
airway infections occured less frequently after initiation of IgG
substitution. On IgG-replacement therapy she has not suffered
from pneumonia since the age of 16 years despite non-adherance
to antibiotic prophylaxis and inhalation of hypertonic saline. She
has never suffered from bacterial otitis, sinusitis, lymphadenitis
or meningitis. At the age of 8 years she developed herpes zoster
(spreading over three dermatomes). The mother did not recall a
prior varicella infection.
At the age of 9 years the girl was admitted with a
fulminant EBV infection with hepatosplenomegaly, pleural as
well as pericardial effusions and ascites. Petechiae and gingival
bleeding due to severe thrombocytopenia were observed. EBV
viral load in plasma was 469.000 copies/ml during the acute
episode. Thereafter, EBV viral load was determined once
to twice yearly and remained between 24.700 and 298.000
copies/ml. Mild thrombocytopenia (131–154/nl), neutropenia
(absolute neutrophil counts 1.1–2.3/nl), elevated liver enzymes,
mild splenomegaly and slightly enlarged intraabdominal and
hilar/mediastinal lymphnodes have been persisting. At the age
of 18 years severe gingivitis and chronic periodontitis with
Abbreviations: AICD, activated induced cell death; BWA, Burrows-
Wheeler Aligner; CADD, combined annotation dependent depletion; CMV,
Cytomegalovirus; CVID, Common variable immunodeficiency; EBV, Epstein-
Barr virus; FACS, Fluorescence activated cell sorting; HLH, Hemophagocytic
lymphohistiocytosis; NK cells, Natural killer cells; LCL, Lymphoblastoid cell line;
PBMC, Peripheral blood mononuclear cells; PFAPA, Periodic fever, aphthous
stomatitis, pharyngitis, and adenitis; PHA, Phytohemagglutinin; PID, Primary
immunodeficiency; PWM, Pokeweed mitogen; PPD, Tuberculin-purified protein
derivative; SAC, S. aureus Cowan strain; SNV, single nucleotide variants; TEMRA,
effector memory T cells re-expresses CD45RA; WES, Whole Exome Sequencing.
FIGURE 1 | (A) Clinical findings. Exposed root surfaces of the teeth 33–43
due to severe gingivitis and periodontitis in an age of 24 years. (B)
Orthopantomogram. General alveolar bone loss caused by severe chronic
periodontitis. The wisdom teeth 18 and 38 are partially erupted and the
mandibular anterior teeth are stabilized by a retainer.
subsequent significant retraction of gingiva and alveolar bone
resorption were diagnosed (Figures 1A,B). High amounts of
EBV DNA were detected in saliva as well as dental plaques,
whereas cytomegalovirus (CMV) DNA was undetectable in
respective samples. No malignancies, especially EBV-associated
lymphoma, were observed up to the age of 24 years. The patient
finished high school and had less than five sick days/year at
university within the last 3 years.
Treatment
The girl was frequently treated with i.v. antibiotics due
to pneumonia. Antibiotic prophylaxis and inhalation with
hypertonic saline was recommended but persistently refused.
Herpes zoster and the primary EBV infection were treated
with i.v. aciclovir and ganciclovir, respectively. Intravenous IgG
substitution was initiated at the age of 7 years with IgG trough
levels between 9 and 10 g/l thereafter.
Immunology
Common variable immunodeficiency (CVID) was diagnosed at
the age of 7 years prior to genetic testing based on decreased IgG,
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TABLE 1A | Total and specific immunoglobulin levels in the patient with CD70
deficiency prior to IgG substitution.
Age 7 Normal range
IgG 4.99 g/l 5.7–13.2
IgA 0.1 g/l* 0.65–2.4
IgM 0.64 g/l* 0.6–1.75
IgE 15.9 kU/l < 330
IgG1 4.45 g/l 3.5–9.1
IgG2 0.12 g/l 0.85–3.3
IgG3 0.41 g/l 0.2–1.04
IgG4 < 0.03//l 0.03–1.577
Anti-Tetanus-Toxoid-IgG < 0.1 IU/ml 0.09–12.8
Anti-PCP-IgG, total 9.7 mg/l 9.2-225.9
Anti-PCP-IgG2 < 1.1 mg/l 0.8–122.4
Anti-Haemophilus-IgG < 0.01 mg/l 0.15–28.5
Blood group IgM isohaemagglutinins
Anti A (titer) 1:2
Anti B (titer) 1:2
*at age >12 years: undetectable IgA, decreased IgM.
anti-PCP, anti-pneumococcal-polysaccharide.
In bold: values below reference range.
IgA and non-detectable specific IgG antibodies against tetanus-
toxoid despite appropriate vaccinations. Furthermore, impaired
polysaccharide responsiveness with low IgG2, IgG4 levels, low
IgM blood group isohemagglutinin titers and non-detectable
or markedly reduced IgG antibodies against haemophilus and
pneumococcal antigens despite recurrent infections due to S.
pneumoniae and H. influenzae (Table 1A).
Lymphocyte differentiation showed increased CD8+ T cells
at all timepoints with normal absolute numbers of CD4+ T
cells and normal number of naive CD4+ and CD8+T cells
(CD4+CD45RA+CCR7+, CD8+CD45RA+CCR7+). Natural
killer (NK) cells were persistently and markedly decreased
(Table 1B). Distributions for other T cell subsets are shown in
Table 1B. B cell differentiation was first examined at the age of
15 years. Transitional B cells (CD19+/CD38++/CD24+)
were persistently increased, switched memory B cells
(CD19+/CD27+/IGD–/IgM–) were within normal ranges
at age 15 and 17 years but decreased since the age of 22
(Table 1C).
Regular T cell proliferation was consistently seen upon
stimulation with mitogens (PHA, IL-2, anti-CD3, PWM,
SAC), whereas proliferation with recall antigens (tetanus-
toxoid, tuberculin purified protein derivate (PPD), candida-
antigen, diphtheria) was normal at the age of 8 years but
markedly decreased thereafter (data not shown). Moreover,
proinflammtory cytokine secretions and activated induced cell
death (AICD) following T cell receptor activation have been
tested and appeared to be normal compared to age-matched
controls (data not shown).
EBV-Specific T Cells
Marked CD4 and CD8T cellular responses toward the EBV
transcription factor BZLF1 and weak responses against EBNA1
and LMP1/2 were observed [for methods see (5), data
not shown].
Genetics
Targeted panel sequencing was performed at the age of 20
years. Among the candidate variants, a homozygous missense
CD70 mutation (ENST00000245903.3:c.2T>C) was found to be
consistent with clinical findings. This variant [g.6591012A>G,
chromosome 19, (GRCh37)] has been previously assigned with
a rsID (rs1290546351) at a frequency of 4,286e-06 in gnomAD
database (1 heterozygous allele count in a total allele count
of 233968). To date, no functional or clinical features have
been reported for this variant. The detected homozygous
variant leads to a predicted start loss as consequence (p.Met1∗)
and is predicted to be deleterious (SIFT) with a combined
annotation dependent depletion score (CADD) of 15.3 using
in silico tools. No alternative downstream in-frame start codon
has been identified. The mutation was verified by Sanger
sequencing. Familial segregation analysis confirmed that the
patient was homozygous for the mutation, while parents were
heterozygous and the healthy brother was homozygous for
the wild type (Figure 2). These results confirmed autosomal
recessive inheritance. Following genetic testing, flow cytometry
analyses of patient activated T cell blasts and B cells confirmed
absence of CD70 expression (Figures 3A–C). Due to limited
accessibility of patient’s samples we were unable to test specific
proliferation or cytotoxicity activity of T cells against EBV-
derived lymphoblastoid cells as described by Izawa et al. and
Abolhassani et al. (2, 6).
Parents
CD70 expression was reduced on parental B cells in blood,
in a EBV-derived lymphoblastoid cell line (LCL) and activated
T cell blasts (Figures 3D,E). Both parents had no history of
frequent or severe infections. IgG, IgA, IgM, IgG subclasses,
specific antibodies to tetanus-toxoid, and pneumococcal antigens
were within normal ranges. Both parents had EBV-specific VCA-
and EBNA-1 IgG-antibodies, EBV DNA in plasma was below
the detection limit (< 1,000 copies/ml). The father also had
severe periodontal disease but no EBV was detected in saliva or
dental plaques.
Extended Family History
In the extended pedigree (seven parental siblings, 20 cousins),
malignancies occurred only in old age in a great uncle (smoker,
lung cancer), and in three great-great parents (cancer of the
larynx, colon and skin, respectively). No other family member
had a history suggestive for CD70 deficiency. However, there
were no further consanguineous marriages within the pedigree.
METHODS
The study including immunologic diagnostic procedures and
genetic analyses was performed in accordance with guidelines
of good clinical practice, the current version of the Declaration
of Helsinki, with written informed consent from the patient,
the brother and the parents and with approval from the local
Institutional Review Board.
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Granulocytes/nl 2.1 (1.8–8.0) 2.3 (1.8–8.0) 1.93 (1.8–8.0) 1.67 (3.0–6.5) 1.72 (3.0–6.5)
Lymphocytes/nl 5.1 (1.1–5.9) 4.2 (1.0–5.3) 2.84 (1.0–5.3) 2.98 (1.5–3.0) 2.48 (1.5–3.0)
Monocytes/nl 0.38 (<0.8) 0.38 (<0.8) 0.38 (<0.8) 0.23 (<0.5) 0.30 (<0.5)
Lymphocyte subpopulations
CD3+ T cells/nl 4.16 (0.7–4.2) 3.57 (0.8–3.5) 2.43 (0.8–3.5) 2.76 (0.9–2.2) 2.24 (0.9–2.2)
CD4+ T cells/nl 2.03 (0.3–2.0) 1.3 (0.4–2.1) 0.71 (0.4–2.1) 0.7 (0.5–1.2) 0.61 (0.5–1.2)
CD8+ T cells/nl 2.03 (0.3–1.8) 2.14 (0.2–1.2) 1.39 (0.2–1.2) 1.75 (0.3–0.8) 1.39 (0.3–0.8)
NK cells (CD56+)/nl 0.08 (0.09–0.90) 0.04 (0.07–1.2) 0.02 (0.07–1.2) 0.01 (0.1–0.4) 0.02 (0.1–0.4)
B cells (CD19+)/nl 0.53 (0.2–1.6) 0.50 (0.2–0.6) 0.39 (0.2–0.6) 0.20 (0.1–0.4) 0.21 (0.1–0.4)
T cell subpopulations
TCR α/β % of CD3 90 (>90) 87 (>90) n.d. 88 (>90) 90 (>90)
TCR γ/δ % of CD3 10 (<10) 13 (<10) n.d. 12 (<10) 10 (<10)
Effector/Memory/ Naïve
Naïve (CD45RA+) % of CD4 57 48 34 53 (16.40–63.20) 46.84 (16.40–63.20)
Memory (CD45RO+) % of CD4 33 n.a. 47 n.a. 60 n.a. 47 (37.04–81.66) 53.16 (37.04–81.66)
Naïve (CD45RA+) % of CD8 n.d. n.d. n.d. 49 46
Memory (CD45RO+) % of CD8 n.d. n.d. n.d. 51 54
Naïve CD45RA+CCR7+ % of CD8 n.d. n.d. n.d. 11.83
(8.22–59.58)
14.06 (8.22–59.58)
TEMRA CD45RA+CCR7– % of CD8 n.d. n.d. n.d. 38.88 (1.67–5.84) 29.18 (1.67–5.84)
Central memory CD45RA–CCR7+ % of
CD8
n.d. n.d. n.d. 0.95 (1.67–5.84) 1.29 (1.67–5.84)
Effector memory CD45RA–CCR7– % of
CD8
n.d. n.d. n.d. 50.34
(22.52–62.25)
55.47 (22.52–62.25)
Naïve CD45RA+CCR7+ % of CD4 n.d. n.d. n.d. 46.43
(17.46–60.24)
46.74 (17.46–60.24)
TEMRA CD45RA+CCR7– % of CD4 n.d. n.d. n.d. 0.35 (2.74–15.54) 0.10 (2.74–15.54)
Central memory CD45RA–CCR7+ % of
CD4
n.d. n.d. n.d. 18.66
(16.40–33.41)
24.63 (16.40–33.41)
Effector memory CD45RA–CCR7– % of
CD4




Treg CD25+/127– % of CD4 n.d. n.d. n.d. 2.42 (3.33–7.6) 5.87 (4.98–9.52)
Naïve Treg (CD45RA+) % of CD4 n.d. n.d. n.d. 1.26 (0.33–3.64) 1.56 (0.33–3.46)
Effector Treg (CD45RA–) % of CD4+ n.d. n.d. n.d. 2.42 (3.33–7.60) 4.32 (3.33–7.60




CD4+/CD31+ n.d. 67 % of CD4
(65–84)




Vα7+CD161+ % of CD3+ n.d. n.d. n.d. n.d. 0.24% (1.0–8.0)
NKT
Vα24+Vb11+CD161+ % of CD3+ n.d. n.d. n.d. n.d. 0.2 >0.02
MAIT, Mucosal-associated invariant T cells; n.a., not available; n.d., not determined; NKT, Natural killer T cells; TEMRA, T effector memory cells re-expressing CD45RA. In bold: values
above or below normal range.
Targeted Sequencing by Next Generation
Sequencing (NGS)
For targeted sequencing, we employed custom-designed targeted
enrichment based on Haloplex technology (Agilent, Santa Clara,
CA) followed by massively parallel sequencing of 625 genes
implicated in immune functions including known PID causing
genes and additional genes recently published or presented at
conferences at the time of the gene panel design. The sample was
sequenced using the Illumina HiSeq3000 system and the cBot
cluster generation instruments as previously described (7, 8),
with minor changes. Briefly, reads were aligned to the human
genome version 19 by means of the Burrows-Wheeler Aligner
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*% of CD19+, in bold: values below or above the reference range.
FIGURE 2 | Identification of start filled loss mutation in CD70. (A) Pedigree of the family in which a homozygous start loss mutation in CD70 was identified. The
genotype of each individual is indicated. The black circle represents the affected individual. (B) DNA electropherograms show the region containing the mutation in
CD70 in the family. The homozygous missense mutation is indicated by an arrow.
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FIGURE 3 | Analysis of CD27 and CD70 expressions in B and T cells of patient. (A) Representative dot-plot FACS analyses of isotype (upper panels), CD27, and
CD70 (lower panels) stainings of control and patient CD4 T cell blasts were depicted. Cells were analysed at day 8 of culture after PHA stimulation. (B) Percentages of
(Continued)
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FIGURE 3 | CD27 and CD70 positive CD4 T cells blasts of 6 healthy donors and the patient are shown in dot plot graph (left and right panels, respectively). Data are
normalised on isotype staining. (C) Flow cytometry analyses of CD19 and CD70 expression in PBMCs of control and parents. (D, left panel), immunoblots for CD70
and Ku70 protein expression in control and parents lysates of lymphoblastoid cell line (LCL). Right panel, representative histogram overlay flow cytometry analysis
corresponding to CD70 (filled) and isotype (unfilled) stainings of activated control and parents LCLs. (E) Representative dot-plot FACS analyses of CD27 and CD70
stainings of control, parents and patient T cell blasts were depicted. Cells were analyzed at day 15 of culture after PHA stimulation. (A–D) Data were obtained from
FACS analysis after cell-specific staining. Data shown are representative of 2 independent experiments and were performed using Flowjo software.
(BWA). VEP was used for annotating single nucleotide variants
(SNVs) and insertions/deletions lists. The obtained list was then
filtered according to the presence of variants with a minor allele
frequency (MAF)>0.01 in 1,000Genomes, gnomAD, and dbSNP
build 149. After further filtering steps for non-sense, missense,
and splice-site variants using VCF. Filter software (9), an internal
database was used to filter out recurrent variants. Moreover,
variants are prioritized using tools, such as SIFT, Polyphen-2
and the CADD score (10), that predict the deleteriousness of a
present variant.
Segregation Analysis
Genomic DNA from peripheral blood cells of patient, her
parents, and brother was isolated according to standard
methods. Oligonucleotide primers flanking the transcription
start codon of CD70 were used to amplify genomic DNA:
forward 5′-GGGCAGGCAACTCTGAGGCT-3′ and reverse
5′- CCTCGCCTCCCTGTTCTGGT-3′. PCR products were
amplified using high fidelity Platinum TaqDNA Polymerase
(Invitrogen) according to the manufacturer’s recommendations,
purified with the QIAquick gel extraction kit (Qiagen) and
sequenced using the ABI PRISM BigDye Terminator Cycle
Sequencing Ready Reaction Kit (PerkinElmer) according to the
manufacturer’s recommendations. All collected sequences were
analyzed using 4peaks software (Version 1.7.2; A. Griekspoor
and T. Groothuis, http://nucleobytes.com/index.php/4peaks).
Cell Cultures
Peripheral blood mononuclear cells (PBMCs) collected from
patient and healthy donors were isolated by Ficoll-Paque density
gradient (Lymphoprep, Proteogenix) from blood samples using
standard procedures. Expansion of T cell blasts was obtained
by incubating PBMCs for 72 h with phytohaemagglutinin (PHA)
(2.5 ug/ml, Sigma-Aldrich) in Panserin 401 (Pan Biotech)
supplemented with 5% human AB serum (Bio West), penicillin
(100 U/ml) and streptomycin (100 ug/ml). After three days, dead
cells were removed by Ficoll-Paque density gradient and blasts
were maintained in culture with IL-2 (100 UI/ml).
Flow Cytometry Analysis
Cell staining and the flow-cytometry-based phenotypic analyses
of PBMCs and cells were performed according to standard
flow cytometry methods. Monoclonal antibodies against CD3
(UCHT1), CD4 (OKT4), CD8 (RPA-T8), CD16 (3G8), CD19
(HIB19), CD25 (BC96), CD27 (LG.3A10), CD28 (CD28.2),
CD31 (WM59), CD45RA (HI100), CD45RO (UCHL1), CD56
(HCD56), CD57 (HNK-1), CD70 (113-16), CD161 (HP-3G10),
CD197 (G043H7), IgM (G20-127), IgD (IA6-2), TCRαβ (IP26),
TCRγδ (B1), IgM (MHM-88), IgD (IA6-2), all purchased from
Beckman Coulter (Krefeld, Germany). Regulatory T cells (Treg)
were determined by extracellular staining using monoclonal
antibodies against CD25 and CD127 (Beckman Coulter) and the
percentage of CD25bright CD127low cells within the CD45RA+
(naïve) or CD45RA– (memory) CD4+ T cell population was
calculated, as described recently (11).
The frequencies of EBV-specific T cells in PBMCs were
determined by EBV peptide stimulation, intracellular cytokine
staining and flow cytometry, as described previously (12). Briefly,
PBMCs were separated from citrate-anticoagulated venous
blood by Biocoll (Biochrom, Berlin, Germany) density gradient
separation and stimulated with overlapping pentadecameric
peptides covering the complete sequences of the EBV proteins
EBNA-1, BZLF, LMP-1, and LMP-2 (all from JPT, Berlin,
Germany), respectively, for 2 h at 37◦C and 5% CO2. DMSO was
added to unstimulated samples (negative control). After addition
of Brefeldin A (10µg/ml, Sigma), samples were incubated
for another 14 h, then washed (PBS containing 0.5% bovine
serum albumin and 0.1% sodium azide) and stained with
anti-CD3 APC-AF750, CD4-ECD, and CD8-PacBlue (all from
Beckman Coulter) antibodies for 30min at 4◦. After washing,
lysis and permeabilization (Perm 2 and Lysis; BD Biosciences,
according to manufacturer’s instructions) cells were stained
intracellularly with anti-TNFa-PE antibodies (all from Beckman
Coulter) for 30min, 4◦. Following staining, cells were washed,
fixed (PBS with 0.5% paraformaldehyde), and stored on ice
until sample acquisition. Samples were measured on a 10-
color Navios flow cytometer and analysed using Navios software
(all Beckman Coulter). The frequency of EBV-specific T cells
was calculated by determining the number of TNFa-producing
CD4+ and CD8+ T cells after antigen stimulation in relation to
unstimulated samples.
All data were collected on a Navios 10-color flow cytometer
(Beckman Coulter) and analyzed using Navios software version
2.0 (Beckman Coulter).
Immunoblots
The following antibodies were used for immunoblotting with
standard procedures: rabbit monoclonal anti-Ku70 (D10A7, Cell
Signaling Technology), rabbit polyclonal anti-CD70 (72094, Cell
Signaling Technology).
Asservation of Gingival Plaques
For each person (patient and her father) 6 supra- and subgingival
plaque samples from maxillary and mandibular sites were
obtained with sterile paper points and placed in 200 µl of sterile
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0.9% sodium chloride solution. The samples from each person
were pooled.
Detection of EBV and CMV DNA in Gingival
Plaques, Saliva and Blood
Real time PCR was used for the detection of CMV DNA targets
the US17 gene, and for EBV the BNRF1 p143 gene, respectively,
as previously described (13, 14). The nucleic acid was extracted
from EDTA plasma (CMV) or from EDTA whole blood (EBV).
To assess an increased sensitivity (95% detection limit is CMV:
330 copies/ml, and EBV: 550 copies/ml, respectively) all reactions
were controlled for presence of inhibiting factors by the use of an
internal co-amplified DNA.
DISCUSSION
A growing number of PIDs with a predominant susceptibility
for EBV-related disorders, e.g., lymphoproliferation, HLH and
lymphoma, has been identified within the last decades. X-linked
inheritance has been shown for SH2D1A, XIAP, and MAGT1,
autosomal recessive inheritance for ITK, CD27, CD70, CTPS1,
RASGRP1, FCGR3A, CD137, and CORO1A mutations [(6, 15)
and reviewed in Latour and Winter (1), Latour and Fischer
(16)]. Six patients with autosomal recessive CD70 deficiency
due to deleterious homozygous mutations have been described
to date (2–4). All patients were alive at the timepoint of
publication, two patients successfully underwent autologous
haematopoietic stem cell transplantation following recurrent
lymphoma and EBV-related lymphoproliferation, respectively.
Four out of six patients presented with EBV-related lymphoma
in childhood. Three patients suffered from recurrent airway
infections, one patient had severe varicella infection, one
a viral encephalitis. One patient presented with recurrent
episodes of fever following primary EBV infection, mimicking
PFAPA (Periodic fever, aphthous stomatitis, pharyngitis, and
adenitis) syndrome. The boy also suffered from severe dental
caries. Hypogammaglobuliemia and/or low/absent specific IgG
antibodies following vaccinations (tetanus, diphtheria) were
observed in all patients.
The presented analyses of parental samples indicate that
expression of CD70 is reduced by about half in cells of
heterozygous carriers, a finding also observed in the study of
Abolhassani and collaborators (3).
The clinical course of our patient further underscores the
heterogeneity of CD70 deficiency, in particular with regard to
EBV-related malignancies in childhood. Our patient suffered
from a severe EBV infection at the age of nine. Up to the age of 24
years, she has been presenting chronic EBV viremia with clinical
signs of EBV-related lymphoproliferation (stable mild splenic
and lymph node enlargement) but she has not suffered from any
EBV-associated malignancy. We assume that the patient is still at
high risk. She was therefore carefully informed about respective
symptoms and has been evaluated clinically on a regular basis.
Several clinical and immunological aspects seen in our
patient were described in CD70-deficient patients before,
e.g., recurrent airway infections, chronic EBV infection,
EBV-mediated lymphoproliferation, hypogammaglobuliemia,
decreased antibodies against tetanus-toxoid, increased CD8+ T
cells, increased transitional B cells and decreased NK cells (in
one patient) (2–4). Novel or specific aspects in our patient are
(a) the impaired polysaccharide responsiveness with very low
polysaccharide specific IgG antibodies, low IgG2, and IgG4 levels,
low IgM blood group isohemagglutinin titers, and recurrent
pneumonia due to encapulated bacteria, (b) very lowNK cells, (c)
chronic EBV viremia over 15 years without the development of a
malignancy, and (d) the severe gingivitis and periodontal disease.
Interestingly, a critical role of herpes viruses – in particular EBV
and CMV – in the pathogenesis and progression of periodontal
disease has been demonstrated within the last years [reviewed in
(17)]: EBVDNA is more frequently detected in periodontal tissue
samples, subgingival plaques or gingival crevicular fluid at sites
of chronic or aggressive periodontitis compared to non-affected
periodontal sites (18). Since EBV can infect periodontal B cells
(19), locally disturbed CD70-CD27-mediated EBV defense in
synergy with periodontopathic bacteria may increase the risk
for severe periodontal disease in CD70-deficient patients. We
therefore advised our patient to ensure proper oral hygiene and
undergo regular professional teeth cleaning/prophylaxis.
The diversity of clinical findings in the low number of
patients with CD70 deficiency demonstrates the critical role
of genetic testing via NGS-based methods in patients with
PID, particularly in the context of consanguinity and early
onset of symptoms. Our patient was first diagnosed with CVID
based on decreased IgG, IgA, and specific antibodies. Prior to
EBV infection she suffered from recurrent viral and bacterial
airway infections. Therefore, CD70 deficiency or other PIDs with
an increased susceptibility to EBV-related lymphoproliferation
would initially not have been considered. Furthermore, EBV-
related lymphoproliferation has been described in several other
PIDs [due to mutations in NFKB1, CTLA4, PIK3CD, PIK3R1,
DOCK8, TYK2, ATM, WAS, and other more, for review
see (20)].
The CD70-CD27 pathway plays a crucial role in the
control of EBV infection. Interestingly, a decrease of CD70
expression on T cells and B cells in heterozygous carriers
does not appear to affect the immune response since the
parents of our patient are asymptomatic, with exception
that the father had also severe periodontal disease. Both
had a positive EBV serology but no history of a severe or
chronic EBV infection. Therefore, the signal induced by half
of CD70 receptors on the surface of LCL seems sufficient
to maintain an efficient immune response to EBV. It is
likely, that other receptors from the TNFR superfamily, like
CD137/CD137L, deliver EBV-specific T cell cosignals required
for their expansion (21).
Collection of clinical and immunologic data from more CD70
deficient patients is needed to improve counseling of affected
families, in particular with regard to anti B cell directed therapies
to reduce EBV reservoirs or stem cell transplantation.
Addendum in proof: Data on a cohort of CD27-
and CD70-deficient patients including our patient were
published following submission of the revised version of this
manuscript (22).
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